Skip to content

Providing Therapeutic program focused on restoring cognitive deficits through specific skill training and compensatory strategies to Mild Alzheimer Disease Patients.

To Study the Effectiveness of Cognitive Rehabilitation on Memory, Language, Attention and Quality of Life in Patients With Mild Alzheimer Disease as Compared to Standard Pharmacological Treatment: A Randomized Controlled Clinical Trial. - CRAD

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/04/004550
Enrollment
40
Registered
2014-04-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Neurologically Diagnosed as Mild Alzheimer Disease.

Interventions

Intervention1: Treatment Group: it would include those Mild Alzheimer Disease patients who consent to the cognitive rehabilitation program along with their pharmacological treatment. this cognitive r

Sponsors

All India Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Education: elementary education and above •Language: both Hindi & English •Medication: stabilized on cholinesterase inhibitors(Donezepil-10mg & Rivastigmine- 12mg as capsule or 10 units as patches). •Subjective memory concern reported by subject or family member •Clinical dementia rating is equal to 1.0 or 2 •Geriatric depression scale less than 6 •Caregiver availability who can accompany the subject to all clinic visits for the duration of the protocol. •Visual and auditory acuity adequate for neuropsychological testing. •Willing and able to participate in a study

Exclusion criteria

Exclusion criteria: • Any significant neurologic disease such as Parkinsonâ??s disease, multi-infarct dementia, Huntingtonâ??s disease, normal pressure hydrocephalus, brain tumour, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities. • Any significant psychiatric illness or substance induced conditions. • Any systemic conditions that are known to cause dementia (hyperthyroidism, vitamin B or folic acid deficiency, niacin deficiency, hypercalcemia, neurosyphilis, HIV infection).

Design outcomes

Primary

MeasureTime frame
The impact of the intervention on the course of the disorder by measuring through - â?¢ Change in the scores of attention concentration measure â?¢ Change in the scores of memory measure â?¢ Change in the scores of verbal fluency measure â?¢ Change in the scores of QOL measure Timepoint: the short term effectiveness would be assessed after 3 months [post cognitive rehabilitation while long term effectiveness would be assessed after 6 months post cognitive rehabilitation.

Secondary

MeasureTime frame
â?¢ Change in the scores of Activities of daily living measure. â?¢ Change in the social support Questionnaire Timepoint: the short term effectiveness would be assessed after 3 months post cognitive rehabilitation while long term effectiveness would be assessed after 6 months post cognitive rehabilitation.

Countries

India

Contacts

Public ContactSwati Bajpai

All India Institute of Medical Sciences

ms.swatibajpai@gmail.com09953022093

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 28, 2026